Clinical Study of ATTR-CM

Phase 4RecruitingNCT04935021

Second Affiliated Hospital, School of Medicine, Zhejiang University100 enrolled

Overview

In this study, patients with ATTR-CM or gene carriers were selected to study the diagnosis and treatment, and long-term follow-up was conducted.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Transthyroxine Amyloidosis Cardiomyopathy

Interventions

ATTR-CMDRUG

Current treatment

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients and gene carriers of ATTR-CM confirmed in the Second Affiliated Hospital of Zhejiang University School of Medicine, regardless of gender, age 18-90 years old; * Patients who have the ability to understand the test and can cooperate with investigators Exclusion Criteria: * Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors

Locations (1)

xiaohong University PAN

Hangzhou, Zhejiang, China

RECRUITING

Outcomes

Primary Outcomes

Rate of cardiovascular death, myocardial infarction, and stroke

Primary Outcome

Time frame: 10 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.